CN217661103U - Medicine percutaneous permeation promoting device - Google Patents
Medicine percutaneous permeation promoting device Download PDFInfo
- Publication number
- CN217661103U CN217661103U CN202123050609.4U CN202123050609U CN217661103U CN 217661103 U CN217661103 U CN 217661103U CN 202123050609 U CN202123050609 U CN 202123050609U CN 217661103 U CN217661103 U CN 217661103U
- Authority
- CN
- China
- Prior art keywords
- module
- electrode
- device body
- energy storage
- coupling
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 31
- 229940079593 drug Drugs 0.000 title claims description 25
- 230000001737 promoting effect Effects 0.000 title description 7
- 230000008878 coupling Effects 0.000 claims abstract description 34
- 238000010168 coupling process Methods 0.000 claims abstract description 34
- 238000005859 coupling reaction Methods 0.000 claims abstract description 34
- 238000004146 energy storage Methods 0.000 claims abstract description 23
- 239000003990 capacitor Substances 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 7
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 239000011229 interlayer Substances 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 3
- 239000002184 metal Substances 0.000 claims description 3
- 210000003491 skin Anatomy 0.000 description 31
- 238000000034 method Methods 0.000 description 8
- 150000002500 ions Chemical class 0.000 description 7
- 210000000434 stratum corneum Anatomy 0.000 description 7
- 238000010586 diagram Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 230000005684 electric field Effects 0.000 description 5
- 238000004520 electroporation Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000013271 transdermal drug delivery Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000012466 permeate Substances 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 229960001193 diclofenac sodium Drugs 0.000 description 2
- 238000007599 discharging Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- JGMJQSFLQWGYMQ-UHFFFAOYSA-M sodium;2,6-dichloro-n-phenylaniline;acetate Chemical compound [Na+].CC([O-])=O.ClC1=CC=CC(Cl)=C1NC1=CC=CC=C1 JGMJQSFLQWGYMQ-UHFFFAOYSA-M 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000002679 ablation Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000011449 brick Substances 0.000 description 1
- 239000000919 ceramic Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000005495 cold plasma Effects 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 230000001808 coupling effect Effects 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 150000002433 hydrophilic molecules Chemical class 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 231100000435 percutaneous penetration Toxicity 0.000 description 1
- 238000009832 plasma treatment Methods 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- FSXQWAWHSKBUFH-UHFFFAOYSA-M sodium;2,3-dichlorophenolate Chemical compound [Na+].[O-]C1=CC=CC(Cl)=C1Cl FSXQWAWHSKBUFH-UHFFFAOYSA-M 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
Images
Landscapes
- Electrotherapy Devices (AREA)
Abstract
The invention discloses a medicine percutaneous permeation-promoting device, wherein a power supply module is arranged in a device body and electrically connected with an energy storage module, the energy storage module is electrically connected with a coupling electrode module, and the coupling electrode module is positioned at the bottom end of the device body and electrically connected with a control module; an ion introduction electrode module is arranged outside the device body and is connected with the power supply module through a lead.
Description
Technical Field
The disclosure belongs to the technical field of medicine percutaneous permeation promotion, and particularly relates to a medicine percutaneous permeation promotion device.
Background
Transdermal drug delivery is a mode of drug delivery through the skin and into the blood to participate in circulation. Compared with the administration modes of oral administration and subcutaneous injection, the transdermal administration prevents the drug from being degraded when passing through intestines and stomach, avoids the first pass effect of liver, ensures that the drug concentration in blood is maintained in a stable range, and is an administration mode with better effect. However, the stratum corneum of the "brick wall" structure in the skin has a strong barrier function, which can prevent external molecules from entering the human body, only a few small-molecule drugs and high lipophilic drugs can naturally permeate through the skin to enter the human body, and hydrophilic molecules and drugs with larger molecular weights cannot naturally permeate through the stratum corneum, that is, most drugs cannot be transdermally administered through natural permeation, and some permeation-promoting methods are needed.
In order to change the permeability of the stratum corneum of the skin, some percutaneous penetration-promoting methods such as chemical enhancers, ultrasound, laser, electroporation, iontophoresis, micro-needle, thermal ablation, etc. have been developed, but the problems of drug penetration-promoting effect, degree of skin irritation to the human body, patient compliance, etc. still need to be solved. Therefore, there is still a need to develop new, effective transdermal penetration enhancing methods. Atmospheric cold plasma is a potentially effective method of transdermal drug delivery where active particles, strong electric fields, heat and ultraviolet light increase skin permeability. Research shows that the plasma generated by jet flow and air dielectric barrier discharge can promote the efficiency of transdermal drug delivery.
The above information disclosed in this background section is only for enhancement of understanding of the background of the application and therefore it may comprise prior art that does not constitute known to a person of ordinary skill in the art.
SUMMERY OF THE UTILITY MODEL
In view of the defects in the prior art, the present disclosure aims to provide a device for promoting drug permeation through skin, which can more effectively promote the drug permeation through the skin surface to the inside under the condition of multi-electric field coupling effect by combining the plasma permeation promoting technology with the existing electroporation and iontophoresis technology.
In order to achieve the above purpose, the present disclosure provides the following technical solutions:
a drug transdermal permeation enhancing device comprising:
the device body is provided with a plurality of grooves,
the device comprises a device body, a power module, an energy storage module, a coupling electrode module and a control module, wherein the power module is arranged in the device body and electrically connected with the energy storage module; the coupling electrode module is sequentially provided with a fixing plate, a flexible insulating interlayer gasket, an electrode assembly, a flaky insulating dielectric plate and a fixing bracket from top to bottom;
an ion introduction electrode module is arranged outside the device body and is connected with the power supply module through a lead.
The device, wherein, the electrode subassembly is formed by coupling 4 high voltage metal electrodes in sheet form.
The apparatus of the present invention, wherein the iontophoresis electrode module includes a positive electrode plate and a negative electrode plate.
The apparatus of, wherein the control module comprises an RC charging circuit.
The device, wherein, still be provided with the boost module in the device body.
The device, wherein, still be provided with voltage conversion module in the device body.
The device, wherein, still be provided with the switching module in the device body to switch coupling electrode mode and iontophoresis mode.
The device, wherein, the power module adopts rechargeable battery pack.
The device, wherein, the energy storage module adopts chargeable electric capacity.
Compared with the prior art, the beneficial effect that this disclosure brought does:
1. the multi-electric field coupling electrode transdermal drug delivery is a non-invasive transdermal permeation promoting mode, and compared with other modes, the mode has weaker irritation to the skin of a human body, so that the patient compliance is better;
2. the method can realize the synergistic permeation promotion of three modes, namely plasma permeation promotion, electroporation permeation promotion and iontophoresis permeation promotion, and has better permeation promotion effect;
3. the plasma treatment of skin can not only promote the percutaneous penetration of the medicine, but also realize the disinfection and sterilization effects.
Drawings
Fig. 1 is a schematic structural diagram of a drug transdermal penetration enhancer device according to an embodiment of the present disclosure;
FIG. 2 is a schematic view of the internal structure of the apparatus shown in FIG. 1;
FIG. 3 is a schematic diagram of the apparatus of FIG. 1 according to another embodiment of the present disclosure;
FIG. 4 is a schematic structural diagram of the coupling electrode module in FIG. 2;
FIG. 5 is a schematic diagram of the operation of the coupled electrode module of FIG. 4 in treating skin;
FIG. 6 is a schematic diagram of the structure of the iontophoresis electrode module of FIG. 2;
fig. 7 is a graph showing the evaluation of the transdermal drug permeation promoting effect by the coupling electrode module.
Detailed Description
Specific embodiments of the present disclosure will be described in detail below with reference to fig. 1 to 7 of the accompanying drawings. While specific embodiments of the disclosure are shown in the drawings, it should be understood that the disclosure can be embodied in various forms and should not be limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the disclosure to those skilled in the art.
It should be noted that certain terms are used throughout the description and following claims to refer to particular components. As one skilled in the art will appreciate, various names may be used to refer to a component. This specification and claims do not intend to distinguish between components that differ in name but not function. In the following description and in the claims, the terms "include" and "comprise" are used in an open-ended fashion, and thus should be interpreted to mean "include, but not limited to. The description which follows is a preferred embodiment of the disclosure, but is made for the purpose of illustrating the general principles of the disclosure and not for the purpose of limiting the scope of the disclosure. The scope of the present disclosure is to be determined by the terms of the appended claims.
To facilitate an understanding of the embodiments of the present disclosure, the following detailed description is to be considered in conjunction with the accompanying drawings, and the drawings are not to be construed as limiting the embodiments of the present disclosure.
In one embodiment, as shown in fig. 1-3, a drug transdermal permeation enhancing device comprises:
the device body is provided with a plurality of grooves,
the device body is internally provided with a power supply module 100, the power supply module 100 is electrically connected with an energy storage module 200, the energy storage module 200 is electrically connected with a coupling electrode module 500, and the coupling electrode module 500 is positioned at the bottom end of the device body and is electrically connected with a control module 300;
an ion introduction electrode module 700 is arranged outside the device body, and the ion introduction electrode module 700 is connected with the power supply module 100 through a lead.
The above embodiment constitutes a complete technical solution of the present disclosure, and the working principle of the solution in the above embodiment is as follows: the bottom of the device body, namely the part provided with the coupling electrode module 500, is placed on the surface of the skin, the device is set to be in a coupling electrode mode, the energy storage module is continuously charged and discharged under the action of the power supply module and acts on the surface of the skin through the coupling electrode module, so that plasma is formed on the surface of the skin to improve the permeability of the stratum corneum of the skin, meanwhile, a high-voltage pulse electric field applied in the plasma generation process acts on the skin, and micropores capable of being naturally recovered are formed in the stratum corneum of the skin in an electroporation mode to facilitate the penetration of drugs; after the permeability of the stratum corneum of the skin is improved, the device is adjusted to an ion introduction mode, the dressing absorbed with the drugs is placed between an ion introduction electrode module and the skin, and the ionic drugs and the polar drugs can enter the skin of a human body under the action of a direct current electric field, so that the synergistic permeation promotion of three modes, namely plasma permeation promotion, electroporation permeation promotion and ion introduction permeation promotion, is realized.
In another embodiment, the coupling electrode module comprises a high voltage electrode and an insulating medium layer for isolating the high voltage electrode from the skin.
In this embodiment, as shown in fig. 4, the coupling electrode module is provided with a fixing plate 501 from top to bottom, and a flexible insulating interlayer gasket 502 is disposed on a lower end surface of the fixing plate 501, so that the coupling electrode module can better adapt to the undulation or flatness of the skin surface. The lower end face of the flexible insulating interlayer gasket 502 is provided with a high-voltage electrode 503, the high-voltage electrode 503 is formed by coupling 4 fan-shaped high-voltage metal electrodes, and the 4 fan-shaped electrodes are located in the same plane and are generally circular. The lower end surface of the high-voltage electrode 503 is closely attached with a sheet-shaped insulating dielectric plate 504 to form an insulating dielectric layer, and preferably, the sheet-shaped insulating dielectric plate 504 is made of ceramic. In the actual treatment process, as shown in fig. 5, the treated area of the skin surface is used as a suspended ground electrode, when the device is set to a coupled electrode mode, the energy storage module starts to charge under the power supply of the power module, when the voltage of the energy storage module increases to a certain degree, the control module controls the conduction of the discharge circuit between the energy storage module 200 and the coupled electrode module 500, the voltage in the energy storage module 200 is boosted by the boosting module 400 and then output to the coupled electrode module, so that the coupled electrode module 500 and the energy storage capacitor form LC oscillation to generate high voltage pulses, the high voltage pulses enable the plasma to be formed in the gap between the sheet-shaped insulating dielectric plate and the treated area of the skin, and meanwhile, a current channel is formed between the sheet-shaped insulating dielectric plate and the skin. In addition, the coupling electrode module further includes a fixing bracket 505, and the coupling electrode module is fixed to the bottom of the apparatus by the fixing bracket 505.
In another embodiment, as shown in fig. 6, the iontophoresis electrode module includes a positive electrode plate 701 and a negative electrode plate 702.
In this embodiment, the power module 100 provides 3-10V dc voltage to the iontophoresis electrode module 700 through the voltage conversion module 600, the positive electrode plate 701 of the iontophoresis electrode module 700 outputs positive voltage, the negative electrode plate 702 of the iontophoresis electrode module 700 outputs negative voltage, the two electrode plates are made of conductive material, and the drug dressing 703 is placed between the two electrode plates and the skin. When the ion introduction electrode module works, the positive electrode plate and the negative electrode plate can form an oriented electric field on the superficial skin layer, so that the medicine with certain conductivity can permeate into a human body through the skin under the action of the oriented electric field.
In another embodiment, the control module includes an RC charging loop.
In this embodiment, the control module 300 controls the energy storage module and the coupling electrode module by using an RC charging loop, where a resistance is recorded as a control resistance, a capacitance is recorded as a control capacitance, and the control capacitance and the energy storage capacitance are charged simultaneously by two secondary sides of one transformer. The resistance value of the control resistor can be adjusted through an external knob switch of the device, after the resistance value is changed, the time for increasing the voltage at two ends of the control capacitor to a certain specific value can be changed, meanwhile, the charging time and the charging speed of the energy storage capacitor can be changed, so that the stored energy can be correspondingly changed, and the regulation and control of the output voltage peak value of the high-voltage electrode in the coupling electrode module 500 between 17 and 22kV and the air discharge frequency between 125 and 200Hz can be further realized.
In another embodiment, a boost module 400 is also disposed within the device body.
In this embodiment, the input end of the boosting module is connected to the energy storage module, the output end of the boosting module is connected to the coupling electrode module, and the electric energy stored in the energy storage module is boosted by the boosting module and then sent to the coupling electrode module, so that the coupling electrode module can output 17-22KV high-voltage pulses.
In another embodiment, a voltage conversion module is further arranged in the device body.
In this embodiment, the input end of the voltage conversion module is connected to the power supply module, the output end of the voltage conversion module is connected to the iontophoresis electrode module, and the power supply module outputs 4.2V of dc voltage, which is converted by the voltage conversion module to provide 3-10V of dc voltage for the iontophoresis electrode module.
In another embodiment, the apparatus further comprises a switching module.
In this embodiment, the switching module is arranged to switch the device between the coupling electrode mode and the iontophoresis mode.
In another embodiment, the power module employs a rechargeable battery pack.
In this embodiment, the rechargeable battery pack is formed by connecting single batteries in parallel, the output voltage is 4.2V, and the power module can provide stable output voltage for the coupling electrode module and the iontophoresis electrode module by means of parallel connection.
In another embodiment, the energy storage module adopts a rechargeable capacitor.
In the embodiment, a capacitor with the capacity of 5 muF is used as the energy storage module, energy is transmitted to the coupling electrode module through the charging and discharging of the capacitor, the energy released by the coupling electrode module during each discharging is the energy stored by the capacitor in the last charging, and an upper limit value exists, so that the use safety is ensured.
The following describes the technical effects of the device according to the present disclosure with reference to specific embodiments.
Sodium dichlorophenolate is used as a tool medicine, the skin of the abdomen of a mouse is used as a treatment object, and a Franz diffusion cell is adopted as an experimental device. Wherein, the experimental group treats the skin with the electrode for 20min, and the control group does not treat the skin. The receiving reservoir of the diffusion cell was filled with a PBS solution, and the skin of the mouse was placed between the diffusion cell and the receiving reservoir with the stratum corneum facing the supply reservoir and fixed after air bubbles were removed. Diclofenac sodium is dissolved by PBS to prepare supersaturated solution, and 3ml of supernatant is added into a supply pool. FIG. 7 is a curve of cumulative permeation of the tool drug per unit area of skin, which is linearly fitted to obtain a slope of the line, i.e., the drug permeation rate, as shown in FIG. 7, the drug permeation rate of the experimental group is 96.87 μ g.h- 1 ·cm- 2 The drug permeation rate of the control group was 14.68. Mu.g.h- 1 Cm-2, the permeation rate of diclofenac sodium in the experimental group is about 6.5 times that of the control group, and therefore, the device disclosed by the disclosure has a good permeation promoting effect on transdermal permeation of the drug.
The present disclosure has been described in detail, and the principles and embodiments of the present disclosure have been explained herein by using specific examples, which are provided only for the purpose of helping understanding the method and the core concept of the present disclosure; meanwhile, for those skilled in the art, according to the idea of the present disclosure, there may be variations in the specific embodiments and the application scope, and in summary, the content of the present specification should not be construed as a limitation to the present disclosure.
Claims (9)
1. A transdermal drug permeation enhancing device, comprising:
the device body is provided with a plurality of grooves,
the device comprises a device body, and is characterized in that a power supply module is arranged in the device body, the power supply module is electrically connected with an energy storage module, the energy storage module is electrically connected with a coupling electrode module, and the coupling electrode module is positioned at the bottom end of the device body and is electrically connected with a control module; the coupling electrode module is sequentially provided with a fixing plate, a flexible insulating interlayer gasket, an electrode assembly, a flaky insulating dielectric plate and a fixing bracket from top to bottom;
an ion introduction electrode module is arranged outside the device body and is connected with the power supply module through a lead.
2. The device of claim 1, wherein the electrode assembly is formed by coupling 4 high voltage metal electrodes in a sheet shape.
3. The apparatus of claim 1, wherein the iontophoresis electrode module includes a positive electrode plate and a negative electrode plate.
4. The apparatus of claim 1, wherein the control module comprises an RC charging loop.
5. The device of claim 1, wherein a boost module is further disposed within the device body.
6. The device of claim 1, wherein a voltage conversion module is further disposed within the device body.
7. The device of claim 1, wherein a switching module is further disposed within the device body to switch the coupling electrode mode and the iontophoresis mode.
8. The device of claim 1, wherein the power module employs a rechargeable battery pack.
9. The apparatus of claim 1, wherein the energy storage module employs a rechargeable capacitor.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202123050609.4U CN217661103U (en) | 2021-12-07 | 2021-12-07 | Medicine percutaneous permeation promoting device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202123050609.4U CN217661103U (en) | 2021-12-07 | 2021-12-07 | Medicine percutaneous permeation promoting device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN217661103U true CN217661103U (en) | 2022-10-28 |
Family
ID=83702593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202123050609.4U Active CN217661103U (en) | 2021-12-07 | 2021-12-07 | Medicine percutaneous permeation promoting device |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN217661103U (en) |
-
2021
- 2021-12-07 CN CN202123050609.4U patent/CN217661103U/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0879070B1 (en) | Iontophoretic treatment system | |
| US5047007A (en) | Method and apparatus for pulsed iontophoretic drug delivery | |
| US5582586A (en) | Drug administration and humor sampling unit and an apparatus therefor | |
| EP2396073B1 (en) | Iontophoretic system for transdermal delivery of active agents for therapeutic and medicinal purposes | |
| WO1997027899A9 (en) | Iontophoretic treatment system | |
| CN111888641B (en) | Iontophoresis drug delivery device | |
| JP2010075710A (en) | Dermal patch | |
| AU2006252145A1 (en) | Synergetic drug delivery device | |
| CN108704218A (en) | A kind of painless dosing paster of skin | |
| JPH0245461B2 (en) | ||
| JPH04224770A (en) | Apparatus for iontophoresis | |
| CN217661103U (en) | Medicine percutaneous permeation promoting device | |
| EP0729370A1 (en) | Iontophoretic drug delivery system and method | |
| Zakzewski et al. | Iontophoretically enhanced transdermal delivery of an ACE inhibitor in induced hypertensive rabbits: preliminary report | |
| CN2460122Y (en) | Therapeutic head of microsonic conductometric skin-through dosage device | |
| US6139537A (en) | Iontophoretic treatment system | |
| KR20110031530A (en) | Ultrasound and RF high frequency integrated fusion system for drug absorption promotion | |
| CN1994489B (en) | Transdermal drug delivery device by using modulated supersonic frequency electric field | |
| CN110352081A (en) | The system of combination including ellagic acid and micro-current | |
| JPH02241464A (en) | Device for iontophoresis | |
| KR101200249B1 (en) | Transdermal drug delivery device | |
| EP0783345A1 (en) | Iontophoretic drug delivery system, including disposable patch and reusable, removable controller | |
| US6235013B1 (en) | Iontophoretic treatment system | |
| WO1996010441A9 (en) | Iontophoretic drug delivery system, including disposable patch and reusable, removable controller | |
| JPH0349589B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant |